Vertigo3d Axsome Therapeutics ( NASDAQ: AXSM ) announced Tuesday that solriamfetol, its experimental therapy for attention deficit hyperactivity disorder (ADHD), reached primary and secondary goals in a Phase 3 trial. Citing data from its six-week FOCUS study designed to evaluate 150 mg and 300.
Back to Health Page
